RxDoctor Payments Data

David Gibbs, MD

Colon & Rectal Surgery · Aiken, SCNPI 1760451272

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $274 and has fallen 53.9% since, to $126 in 2025. That places this record below the midpoint for colon & rectal surgery clinicians in SC, where the typical reported total is $1,631.

$883in general payments, 2019–2025

Across 47 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$173
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$129
  • TELA Bio, Inc.$87
  • Johnson & Johnson$77
  • Organogenesis Inc.$51
  • Neuraxis, Inc.$46
  • plus $320 from 15 others

What the payments were for

  • Food & beverage$883100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$883 in reported general payments places this provider in the 40th percentile of 35 colon & rectal surgery providers in South Carolina.

See all colon & rectal surgery providers in South Carolina

Medicare billing

Part B allowed, 2024
$129,363
Medicare patients
520
Services billed
943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide49$38,001
Colestipol Hcl67$5,100
Famotidine199$1,936
Hydrocortisone11$1,390
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine31$754
Omeprazole66$400
Esomeprazole Magnesium25$275
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen12$68
Metoclopramide Hcl18$67
Ondansetron OdtOndansetron12$40
Amoxicillin15$25

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$173$38,00149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 35 colon & rectal surgery providers in South Carolina.

Other colon & rectal surgery in Aiken

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →